Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Wandercraft Closes $45 Million Series C Financing to Accelerate Delivery of the World’s First Personal Self-Balanced Exoskeleton
Wandercraft, a leading healthtech company in dynamic robotics and exoskeleton technology, announced today a $45 million equity […]
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis […]
SCIENION Partners with Institute for Prevention and Occupational Medicine (IPA) to Develop UROfast, a Rapid Bladder Cancer Diagnostics Platform
Today SCIENION, a BICO company and leading developer of miniaturized multiplex diagnostic tests, announced a […]
PhoreMost Expands into New Facility at Unity Campus, Cambridge, UK
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced […]
Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors
Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform […]
Ori Biotech Raises Over $100 Million in Series B Funding to Launch Innovative Cell and Gene Therapy Manufacturing Platform
Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces […]
DaVita Acquires MedSleuth, Deepens Efforts to Improve Transplant Experience
DaVita Inc. today announced its acquisition of transplant software company MedSleuth. Working with transplant centers across […]
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]
ReviR Therapeutics Raises ~$20M in Pre-A Financing
ReviR Therapeutics, a South San Francisco based biopharmaceutical company, completed a Pre-A financing round with ~$20M. The funds […]
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more